Composition for preventing, improving or treating allergic diseases or itching, comprising pentapeptide as an active ingredient

A pentapeptide composition addresses the limitations of current treatments by suppressing β-hexosaminidase and inflammatory cytokines, effectively managing allergic diseases and improving skin conditions.

JP7577765B2Active Publication Date: 2024-11-05CAREGEN
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2022575918
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-06-12
Filing Date
2021-06-11
Publication Date
2024-11-05
Estimated Expiration
2041-06-11

AI Technical Summary

Technical Problem

Current treatments for allergic diseases, such as atopic dermatitis, primarily focus on symptomatic relief and have limited efficacy in addressing the underlying immune response, often causing side effects, and there is a need for a more effective and safer therapeutic approach.

Method used

A pharmaceutical and cosmetic composition containing a pentapeptide with the amino acid sequence of SEQ ID NO: 1 is developed to suppress the release of β-hexosaminidase and inflammatory cytokines, thereby reducing allergic reactions and improving skin conditions.

Benefits of technology

The pentapeptide effectively suppresses mast cell degranulation, reduces itching, and improves skin barrier function, providing significant relief for allergic diseases like atopic dermatitis with minimal side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007577765000003
    Figure 0007577765000003
  • Figure 0007577765000004
    Figure 0007577765000004
  • Figure 0007577765000005
    Figure 0007577765000005
Patent Text Reader

Abstract

The present invention relates to a composition for preventing, ameliorating or treating allergic diseases or itching, which contains a pentapeptide as an active ingredient.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the use of pebapeptide for the prevention, amelioration or treatment of allergic diseases or itch. [Background technology]

[0002] Mast cells and blood basophils are known to be cells in the body that induce various allergic diseases by secreting cytokines. These cells have a receptor (FcεRI) for IgE, an antibody that induces allergies, on the cell surface, and when stimulated by an allergy-inducing substance (called an antigen or allergen), they secrete various allergy-inducing substances that they possess (Amin K., Respiratory Medicine., 2012).

[0003] Atopic dermatitis (AD), one of the allergic diseases, is a late-onset inflammatory skin disease caused by genetic, environmental and immunological abnormal reactions and the breakdown of the skin barrier, which leads to xerosis, pruritus and erythematous eczema. In recent years, the prevalence of AD has been increasing due to global environmental changes, dietary habits and environmental pollution, and interest in solutions is also increasing.

[0004] Although the exact cause of atopic dermatitis remains unknown, immunological features that emerge during disease progression include a significant increase in circulating IgE antibody levels and increased levels of interleukin-4 (IL-4) expression, while interferon gamma (IFNγ) expression decreases (Boguniewicz and Beltrani, 2002; Abdel Hamid, 2003). IgE binds to two isoforms of circulating IgE receptors: the high-affinity IgE receptor (FcεRI) is present on the surface of mast cells and basophilic leukocytes, and the low-affinity IgE receptor (FcεRII or CD23) is present on lymphocytes, oxyleukocytes, platelets, and macrophages. Symptoms of allergic disease are initiated by cross-linking of IgE receptors on mast cells and the eventual degranulation of mast cells after exposure to allergens. Molecules released by mast cells include histamine, heparin, proteases and free radicals, which mediate diverse biological effects such as vasodilation, intestinal and / or bronchial smooth muscle contraction, mucus secretion and local protein secretion. The early mast cell mediated response leads to an influx of oxyntic leukocytes, basolytic leukocytes and lymphocytes 6-24 hours later. This late stage response induces chronic inflammation of tissues that are continually exposed to antigens.

[0005] In general, medicines such as antihistamines, steroidal or nonsteroidal anti-inflammatory drugs, and leukotriene antagonists are used to treat allergic diseases. Although these medicines are mainly useful for symptomatic effects, they cannot provide the treatment required for the fundamental cure of allergic diseases, such as alleviating excessive humoral immunity or suppressing IgE production. In addition, topical steroid preparations can cause various side effects such as skin atrophy, vasodilation, depigmentation, and the development of stretch marks when used for a long period of time.

[0006] Thus, the present inventors have confirmed that the newly synthesized pentapeptide can be useful for preventing, ameliorating or treating allergic diseases including atopic dermatitis, and have completed the present invention. Summary of the Invention [Problem to be solved by the invention]

[0007] An object of the present invention is to provide a pharmaceutical composition for preventing or treating allergic diseases.

[0008] Another object of the present invention is to provide a cosmetic composition for preventing or ameliorating allergic diseases.

[0009] It is still another object of the present invention to provide a composition for preventing or improving itching.

[0010] It is still another object of the present invention to provide a method for preventing or treating allergic diseases.

[0011] It is still another object of the present invention to provide a peptide for use in the prevention or treatment of allergic diseases.

[0012] It is yet another object of the present invention to provide a method for preventing or treating itch.

[0013] It is still another object of the present invention to provide a peptide for use in the prevention or treatment of itch. [Means for solving the problem]

[0014] Therefore, one aspect of the present invention provides a pharmaceutical composition for preventing or treating an allergic disease, which comprises a pentapeptide consisting of the amino acid sequence (KFLIK) of SEQ ID NO:1 as an active ingredient.

[0015] Another aspect of the present invention provides a cosmetic composition for preventing or ameliorating an allergic disease, comprising a pentapeptide consisting of the amino acid sequence of SEQ ID NO:1 as an active ingredient.

[0016] Yet another aspect of the present invention provides a method for preventing or treating an allergic disease, comprising administering to an individual a pentapeptide consisting of the amino acid sequence of SEQ ID NO:1.

[0017] Yet another aspect of the present invention provides a pentapeptide consisting of the amino acid sequence of SEQ ID NO: 1 for use in the prevention or treatment of an allergic disease.

[0018] Yet another aspect of the present invention provides a composition for preventing or ameliorating itching, comprising a pentapeptide consisting of the amino acid sequence of SEQ ID NO:1 as an active ingredient.

[0019] Yet another aspect of the present invention provides a method for preventing or treating itch, comprising the step of administering to an individual a pentapeptide consisting of the amino acid sequence of SEQ ID NO:1.

[0020] Yet another aspect of the present invention provides a pentapeptide consisting of the amino acid sequence of SEQ ID NO: 1 for use in the prevention or treatment of itch. Effect of the Invention

[0021] The pentapeptide of the present invention consisting of the amino acid sequence of sequence number 1 suppresses the release of β-hexosaminidase, which induces itching and inflammatory responses, and significantly reduces the expression of inflammatory cytokines secreted by cellular immune responses, and can therefore be used to prevent, improve or treat various allergic diseases, including atopic dermatitis.

[0022] However, the effects of the present invention are not limited to those mentioned above, and other effects not mentioned will be clearly understood by those skilled in the art from the following description. [Brief description of the drawings]

[0023] [Figure 1a] FIG. 1 shows the results of evaluating the thermal stability of the KFLIK peptide. The results show the high-temperature stability of the peptide when stored for a long period at 45° C. [Figure 1b] FIG. 1 shows the results of evaluating the thermal stability of the KFLIK peptide: the results of confirming the high-temperature stability of the peptide at the maximum heating temperature (121° C.) are shown. [Diagram 2] 1 is a graph showing changes in the amount of β-hexosaminidase released by mast cells upon treatment with KFLIK peptide. [Diagram 3] 1 is a graph showing changes in expression of inflammatory cytokines (IL-3, IL-4, and TNF-α) by treatment of mast cells with KFLIK peptide. [Figure 4] 1 is a graph showing changes in the expression of inflammatory cytokines (TNF-α, IL-1β, and COX-2) by treatment of splenocytes with KFLIK peptide. [Figure 5a] 1 is a graph showing the effect of the KFLIK peptide of the present invention on improving atopic dermatitis through human efficacy evaluation: the graph shows the skin moisture change rate (%) in the lesion area. [Figure 5b] 1 is a graph showing the effect of the KFLIK peptide of the present invention on improving atopic dermatitis through human efficacy evaluation: the graph shows the rate of change (%) in transepidermal water loss at the lesion site. [Figure 5c] 1 is a graph showing the effect of the KFLIK peptide of the present invention on improving atopic dermatitis through human efficacy evaluation: the change rate (%) of skin itching index at the lesion site is shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0024] The present invention will be described in detail below.

[0025] One aspect of the present invention provides a pharmaceutical composition for preventing or treating allergic diseases, comprising as an active ingredient a pentapeptide consisting of the amino acid sequence of SEQ ID NO: 1. As used herein, the term "peptide" refers to a linear or cyclic molecule formed by binding amino acid residues to each other through peptide bonds. The peptide may be prepared by conventional biological or chemical synthesis methods known in the art, such as solid-phase synthesis techniques.

[0026] As used herein, the term "pentapeptide" refers to a linear molecule consisting of five amino acid residues, and the pentapeptide of the present invention refers to a linear peptide molecule composed of the amino acid sequence of SEQ ID NO:1 (KFLIK).

[0027] The "peptide" and "pentapeptide" may be an amino acid variant or fragment having a different sequence due to deletion, insertion, substitution, or a combination thereof of amino acid residues, within a range that does not affect the function. Amino acid replacement that does not change the overall activity of the peptide is known in the art. In some cases, the peptide may be modified by phosphorylation, sulfation, acrylation, glycosylation, methylation, farnesylation, etc. Therefore, the present invention includes a peptide having substantially the same amino acid sequence as the pentapeptide composed of the amino acid sequence of KFLIK, and a variant thereof, or an active fragment thereof. The substantially identical protein means an amino acid sequence having 75% or more, preferably 80% or more, for example 85% or more, 90% or more, 95% or more, 98% or more, or 99% or more sequence homology with the amino acid sequence of KFLIK, but is not limited thereto, and is within the scope of the present invention as long as it has 75% or more amino acid sequence homology and the same activity. Additionally, the peptides of the present invention may further comprise targeting sequences, tags, designated residues, or specifically engineered amino acid sequences to increase half-life or peptide stability.

[0028] In addition, a protecting group may be attached to the N-terminus or C-terminus of the peptide of the present invention to obtain better chemical stability, enhanced pharmacological properties (half-life, absorbency, potency, efficacy, etc.), altered specificity (e.g., broader biological activity spectrum), and reduced antigenicity. For example, the protecting group may be an acetyl group, a fluorenylmethoxycarbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group, or a polyethylene glycol (PEG), and may include any component that can enhance the modification of the peptide, particularly the stability of the peptide, without limitation. The term "stability" is used to mean not only in vivo stability that protects the peptide of the present invention from attack by in vivo protease, but also storage stability (e.g., room temperature storage stability).

[0029] The pentapeptide of the present invention consisting of the amino acid sequence of KFLIK can prevent or treat allergic diseases by suppressing the expression of inflammatory cytokines IL-3, IL-4, TNF-α, IL-1β and COX-2 secreted in immune responses.

[0030] Furthermore, the pentapeptide of the present invention consisting of the amino acid sequence of KFLIK can prevent or treat allergic diseases by reducing the release of β-hexosaminidase, which induces itching and inflammatory reactions in mast cells.

[0031] In addition, the pentapeptide of the present invention consisting of the amino acid sequence of KFLIK exhibits effects of moisturizing the skin, improving the skin barrier and alleviating itching at the lesion site of atopic dermatitis, and can improve or prevent the symptoms of atopic dermatitis.

[0032] The term "allergic disease" refers to a disease caused by an allergic reaction caused by an excessive immune response in the body against an external antigen, and specifically may be one or more diseases selected from the group consisting of edema, anaphylaxis, allergic rhinitis, asthma, allergic conjunctivitis, allergic dermatitis, contact dermatitis, urticaria, pruritus, insect allergy, food allergy, and drug allergy, but is not limited thereto.

[0033] The allergic dermatitis may be atopic dermatitis.

[0034] The above-mentioned "atopic dermatitis" refers to a type of allergic disease, a skin disease accompanied by symptoms such as itching, dry skin, increased skin thickness, and characteristic eczema.

[0035] The term "prevention" refers to any action that inhibits or delays the onset of a disease by administering the pentapeptide or composition.

[0036] The "treatment" or "amelioration" means any action in which the symptoms of the disease are improved or significantly altered by administration of the pentapeptide or composition. The pharmaceutical composition for preventing or treating allergic diseases according to the present invention can be formulated and used in the form of oral preparations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injection solutions by a conventional method, and may contain suitable carriers, excipients, or diluents that are conventionally used in the manufacture of pharmaceutical compositions for formulation.

[0037] The pharma- ceutically acceptable carrier may include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia, gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, and the like, which are commonly used in formulations.

[0038] The pharmaceutical composition may further contain, in addition to the above ingredients, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, and the like.

[0039] The pharmaceutical composition can be administered orally or parenterally (e.g., intramuscularly, intravenously, intraperitoneally, subcutaneously, intradermally, or topically) depending on the desired method, and the dosage varies depending on the condition and weight of the patient, the degree of the disease, the form of the drug, the route and time of administration, and may be appropriately selected by those skilled in the art.

[0040] The pharmaceutical composition of the present invention is administered in a pharma- ceutical effective amount. In the present invention, the term "pharma-ceutical effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to any medical treatment, and the level of an effective dose may be determined by factors including the type and severity of the patient's disease, the activity of the drug, sensitivity to the drug, administration time, administration route and excretion rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field. The pharmaceutical composition may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered simultaneously, separately, or sequentially with conventional therapeutic agents, and may be administered singly or in multiple doses. It is important to administer an amount that can obtain maximum effect with minimum amount without side effects, taking into consideration all of the above factors, and this can be easily determined by those skilled in the art.

[0041] The effective amount of the pharmaceutical composition may vary depending on the age, sex, condition, and weight of the patient, the degree of absorption of the active ingredient into the body, the inactivation rate, the excretion rate, the type of disease, and drugs used in combination, and may be increased or decreased depending on the administration route, the severity of obesity, sex, weight, age, and the like. For example, the pharmaceutical composition may be administered in an amount of about 0.0001 μg to 500 mg, preferably 0.01 μg to 100 mg, per kg of patient body weight per day.

[0042] In another aspect, the present invention provides a cosmetic composition for improving or alleviating an allergic disease, comprising a pentapeptide consisting of the amino acid sequence of SEQ ID NO:1 as an active ingredient.

[0043] The specific details of the peptide, pentapeptide, allergic disease, and atopic dermatitis are as described above.

[0044] The cosmetic composition may be prepared in any formulation commonly used in the art, such as, but not limited to, a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleanser, oil, powder foundation, emulsion foundation, wax foundation, spray, and the like.

[0045] The cosmetic composition may be prepared in various forms such as a solution such as a softening lotion, a nourishing lotion, a nourishing cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray, a powder, a hair tonic, a hair cream, a hair lotion, a hair shampoo, a hair rinse, a hair conditioner, a hair spray, a hair aerosol, a pomade, a gel, a sol-gel, an emulsion, an oil, a wax, an aerosol, etc., but is not limited thereto.

[0046] The cosmetic composition of the present invention may contain other additives such as excipients and carriers in addition to the pentapeptide consisting of the amino acid sequence of KFLIK, and it is possible to apply and incorporate as many ordinary ingredients as necessary that are incorporated into general skin cosmetics.

[0047] When the cosmetic composition is in the form of a paste, cream or gel, the carrier component may be an animal oil, a vegetable oil, a wax, a paraffin, a starch, a tragacanth, a cellulose derivative, a polyethylene glycol, a silicone, a bentonite, a silica, a talc or a zinc oxide.

[0048] When the cosmetic composition is in the form of a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder may be used as a carrier component, and particularly when the cosmetic composition is in the form of a spray, a propellant such as chlorofluorohydrocarbon, propane / butane, or dimethyl ether may be additionally included, but is not limited thereto.

[0049] When the cosmetic composition is in the form of a solution or emulsion, a solvent, solubilizer, or emulsifier may be used as a carrier component, and for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic esters, polyethylene glycol, or fatty acid esters of sorbitan may be used.

[0050] When the cosmetic composition is in the form of a suspension, the carrier component may be a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethyl sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tragacanth.

[0051] When the cosmetic composition is in the form of a surfactant-containing cleanser, the carrier component may be fatty alcohol sulfate, fatty alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkylamido betaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester.

[0052] When the cosmetic composition is in the form of a hair shampoo, the Trolox-peptide conjugate of the present invention may be mixed with base components for forming a shampoo, such as a thickener, a surfactant, a viscosity regulator, a moisturizer, a pH regulator, a preservative, and an essential oil. The thickener may be CDE, the surfactant may be LES, which is an anionic surfactant, and cocobetaine, which is an amphoteric surfactant, the viscosity regulator may be polyquaternary, the moisturizer may be glycerin, and the pH regulator may be citric acid or sodium hydroxide. The preservative may be grapefruit extract, and other essential oils such as cedarwood, peppermint, and rosemary, silk amino acid, pentaol, or vitamin E may be added.

[0053] In addition to the pentapeptide of the present invention and a carrier component as active ingredients, the components contained in the cosmetic composition may further include components commonly used in cosmetic compositions, such as, for example, common adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, pigments, and fragrances, but are not limited thereto.

[0054] In another aspect, the present invention provides a composition for preventing or ameliorating itching, comprising a pentapeptide consisting of the amino acid sequence of SEQ ID NO:1 as an active ingredient.

[0055] The present invention also provides a method for preventing or treating itch, comprising the step of administering to an individual a pentapeptide consisting of the amino acid sequence of SEQ ID NO:1.

[0056] The present invention also provides a pentapeptide consisting of the amino acid sequence of SEQ ID NO: 1 for use in the prevention or treatment of itch.

[0057] The specific details of the peptide, pentapeptide, prevention, and improvement are as described above.

[0058] The term "itch" refers to a skin condition that induces an unpleasant sensation of wanting to scratch, and can be used interchangeably with "pruritus." Examples of the "itch" include, but are not limited to, itching caused by allergic diseases such as urticaria, psoriasis, and atopic dermatitis, itching caused by ultraviolet rays, scalp itching, heat rash, sores, frostbite, and senile pruritus.

[0059] The present invention also provides a method for preventing or treating an allergic disease, comprising administering to an individual a pentapeptide consisting of the amino acid sequence of SEQ ID NO:1.

[0060] The term "subject" may include a human. The term "subject" may also refer to a subject in need of the administration of the pentapeptide of the present application, and the subject in need of the administration may include not only individuals who have been diagnosed with an allergic disease or itch, or individuals who have symptoms associated with an allergic disease or itch, but also individuals who wish to administer the administration to prevent the onset of the disease or symptoms or to improve their health.

[0061] The term "administration" means providing a predetermined substance to a patient by any suitable method, and the administration route of the composition of the present invention may be oral or parenteral administration via any common route as long as it can reach the target tissue. In addition, the composition may be administered by any device that can transfer the active substance to the target cell.

[0062] The present invention provides a pentapeptide consisting of the amino acid sequence of SEQ ID NO: 1 for use in the prevention or treatment of allergic diseases.

[0063] As described above, the pentapeptide of the present invention has the effect of suppressing degranulation of mast cells, reducing the amount of β-hexosaminidase released, and suppressing the expression of inflammatory cytokines, thereby suppressing itching and inflammatory reactions, and therefore can be used as a raw material for pharmaceutical or cosmetic compositions intended to prevent, improve, or treat allergic diseases or itching.

[0064] The present invention will be described in detail below with reference to examples and experimental examples.

[0065] However, the following examples and experimental examples are merely intended to illustrate the present invention, and the contents of the present invention are not limited to the following examples and experimental examples.

[0066] [Example 1] Synthesis and characterization of a novel pentapeptide 1-1. Synthesis of pentapeptides The novel peptide sequence "KFLIK" consisting of the amino acid sequence of SEQ ID NO: 1 was produced by a known method. The molecular weight of the peptide containing the amino acid sequence of SEQ ID NO: 1 was measured using a molecular weight measuring device, and it was confirmed that the molecular weight was 647.4 Da.

[0067] 1-2. Evaluation of high temperature stability during long-term storage The peptide of the present invention consisting of the amino acid sequence of SEQ ID NO: 1 was dissolved in sterilized distilled water at a concentration of 1000 ppm and stored at 45°C for 7, 14, 28, 60 and 75 days, and then subjected to HPLC analysis.

[0068] As a result, as shown in FIG. 1a, it was confirmed that the peptide of the present invention maintained stability for a maximum observation period of 75 days at 45° C.

[0069] 1-3.Evaluation of high temperature stability The peptide of the present invention was dissolved in sterilized distilled water at a concentration of 1000 ppm, heated at 121° C. for 15 minutes and 30 minutes, and then subjected to HPLC analysis.

[0070] As a result, as shown in FIG. 1b, it was confirmed that the peptide of the present invention maintained stability for the maximum heating time of 30 minutes at 121° C.

[0071] [Experimental Example 1] Inhibitory effect of pentapeptide treatment on degranulation in mast cells In order to confirm the effect of the pentapeptide of the present invention in suppressing allergic inflammatory reactions and improving atopic dermatitis, the degree of degranulation was examined using mast cells (rat basophilic leukemia cell line, RBL-2H3).

[0072] Specifically, 5 × 10 RBL-2H3 cells were 5 After inoculation into a 12-well plate at a density of 1.5 cells / well, the cells were cultured overnight in a 5% CO2 incubator at 37°C. DNP-IgE was added to the complete medium for sensitization. After 3 hours, the cells were washed three times with DPBS, and then PIPES buffer was added. The cells were pretreated with the pentapeptide of the present invention synthesized in Example 1 for 30 minutes, and then treated with DNP-HSA for 3 hours to induce an immune response. Then, 25μL of the supernatant was collected, and 25μL of a substrate solution (5mM p-nitrophenyl-N-acetyl-β-D-glucosaminide dissolved in 0.2M sodium citrate buffer, pH4.5) was added, followed by incubation at 37°C for 90 minutes for reaction. After the reaction, 200μL of stop solution (0.1M Na2CO3 / NaHCO3, pH10.0) was added to each well to stop the enzyme reaction, and the absorbance was measured at 405nm using a microplate reader. The β-hexosaminidase secreted from the supernatant was quantified by adding a 0.5% Triton X-100 solution to the cells and using the following mathematical formula 1.

[0073] [Formula 1] % release=(experimental β-hexosaminidase release-spontaneous β-hexosaminidase release) / total cellular β-hexosaminidase × 100

[0074] As a result, as shown in Figure 2, in the control group (NC) in which the immune response was induced with DNP-IgE and DNP-HSA, the amount of β-hexosaminidase released was significantly increased compared to normal mast cells (NON). However, when the pentapeptide of the present invention was treated at 10 μM or 100 μM while the immune response was induced with DNP-IgE and DNP-HSA, the amount of β-hexosaminidase released decreased in a concentration-dependent manner.

[0075] This indicates that the pentapeptide of the present invention can effectively inhibit the degranulation of mast cells by reducing the amount of β-hexosaminidase released from mast cells, thereby suppressing itching and inflammatory responses.

[0076] [Experimental Example 2] Inhibitory effect of pentapeptide treatment on the expression of inflammatory cytokines in mast cells In order to confirm the effect of the pentapeptide of the present invention in suppressing allergic inflammatory reactions and improving atopic dermatitis, the expression of inflammation-related cytokines was examined using mast cells (rat basophilic leukemia cell line, RBL-2H3).

[0077] Specifically, 5 × 10 RBL-2H3 cells were 5After seeding at a density of 1000 cells / well on a 12-well plate, the cells were cultured overnight in a 37°C, 5% CO2 incubator. DNP-IgE was added to the complete medium for sensitization. After 3 hours, the cells were washed three times with DPBS and then PIPES buffer was added. In addition, the cells were pretreated with the pentapeptide of the present invention synthesized in Example 1 for 30 minutes, and then treated with DNP-HSA for 2 hours to induce an immune response. Ketotifen (20 μg / mL) was used as a positive control.

[0078] After that, the cells were harvested, RNA was isolated, and cDNA was synthesized from the isolated RNA using a cDNA synthesis kit (Intron, Korea). Polymerase chain reaction was performed using the synthesized cDNA, PCR premix (Intron, Korea), and IL-3, IL-4, and TNF-α primers, and the amplified PCR products were electrophoresed on an agarose gel to confirm DNA bands. The primer sequences used are as shown in Table 1.

[0079] [Table 1]

[0080] As a result, as shown in FIG. 3, in control cells (NC) sensitized with DNP-IgE and induced with an immune response using DNP-HSA, the expression of inflammatory cytokines IL-3, IL-4, and TNF-α was significantly increased compared to normal mast cells (NON). Meanwhile, when cells were sensitized with DNP-IgE and induced with an immune response using DNP-HSA, and then treated with the pentapeptide of the present invention, the expression of all inflammatory cytokines that had increased in the immune response was significantly decreased. This demonstrates that the pentapeptide of the present invention suppresses allergic inflammatory responses and is effective in improving atopic dermatitis.

[0081] [Experimental Example 3] Inhibitory effect of pentapeptide treatment on the expression of inflammatory cytokines in splenocytes In order to confirm the effect of the pentapeptide of the present invention in suppressing allergic inflammatory reactions and improving atopic dermatitis, the expression pattern of inflammation-related cytokines was confirmed using mouse spleen cells.

[0082] Specifically, mouse spleen cells were isolated and cultured at 1 x 10 7 The cells were seeded in a 24-well plate at a density of 1000 cells / well and then cultured overnight in a 5% CO2 incubator at 37°C. After replacing the medium with serum-free medium, the cells were treated with the pentapeptide of the present invention and TNF-α 4 hours later and cultured for 30 minutes. Ketotifen (20 μg / mL) was used as a positive control.

[0083] After that, the cells were harvested, RNA was isolated, and cDNA was synthesized using a cDNA synthesis kit (Intron, Korea). Polymerase chain reaction was performed using the synthesized cDNA, PCR premix (Intron, Korea), and TNF-α, IL-1β, and COX-2 primers, and the amplified PCR products were electrophoresed on an agarose gel to confirm DNA bands. The primer sequences used are as shown in [Table 2].

[0084] [Table 2]

[0085] As a result, as shown in FIG. 4, in the control cells in which an immune response was induced with TNF-α, the expression of inflammatory cytokines TNF-α, IL-1β, and COX-2 was significantly increased compared to normal spleen cells. Meanwhile, when the pentapeptide of the present invention was treated with spleen cells together with TNF-α, IL-1β, and COX-2, the expression of all inflammatory cytokines increased by the immune response was significantly decreased. Through this, it can be seen that the pentapeptide of the present invention has the effect of suppressing allergic inflammatory responses and improving atopic dermatitis.

[0086] [Experimental Example 4] Clinical trial results of improving atopic dermatitis A human efficacy evaluation was conducted on 21 atopic dermatitis patients to evaluate the relieving itching caused by dry skin. The dry skin lesions were used as test sites, and instrumental measurements were performed on the affected areas before use, after two weeks of use, and after four weeks of use.

[0087] The effect of improving atopic dermatitis was confirmed by measuring skin moisture using a Comemeter CM825, measuring skin moisture loss using a Tewameter TM300, and assessing the improvement of itching (VAS).

[0088] 4-1. Production of serums and creams containing pentapeptides In order to confirm the effect of the pentapeptide in improving atopic skin symptoms, serum and cream were prepared so that the pentapeptide of the present invention synthesized in Example 1 was contained at 2000 ppm.

[0089] 4-2. Skin moisturizing effect As shown in FIG. 5a, the use of the pentapeptide-containing serum and cream of the present invention was confirmed to have a statistically significant effect on improving skin moisture in the affected area (2 weeks and 4 weeks of use; P<0.05).

[0090] 4-3. Effect of improving the skin barrier at the affected area As shown in FIG. 5b, when serum and cream containing the pentapeptide of the present invention were used, a statistically significant improvement in transepidermal water loss was observed in the affected area [change in transepidermal water loss (%)=(after-before) / before*100].

[0091] 4-4. Effect of improving itching As shown in FIG. 5c, it was also confirmed that when serum and cream containing the pentapeptide of the present invention were used, the itching index was statistically significantly improved after 2 and 4 weeks compared to before application.

[0092] As a result, the peptide serum and cream of the present invention exhibit the effects of moisturizing the skin, improving the skin barrier, and alleviating itching, and can be used as a functional material for alleviating skin pruritus, moisture, and itching caused by dry skin such as atopy.

Claims

1. A pharmaceutical composition for preventing or treating an allergic disease, comprising as an active ingredient a pentapeptide consisting of the amino acid sequence of SEQ ID NO:

1.

2. The pharmaceutical composition according to claim 1, wherein the allergic disease is one or more selected from the group consisting of edema, anaphylaxis, allergic rhinitis, asthma, allergic conjunctivitis, allergic dermatitis, contact dermatitis, urticaria, pruritus, insect allergy, food allergy, and drug allergy.

3. The pharmaceutical composition according to claim 2 , wherein the allergic dermatitis is atopic dermatitis.

4. 2. The pharmaceutical composition of claim 1, wherein the pentapeptide i) inhibits the expression of IL-4, IL-3 and TNF-α in mast cells, ii) inhibits the expression of TNF-α, IL-1β and COX-2 in spleen cells, and iii) inhibits the release of β-hexosaminidase in mast cells.

5. The pharmaceutical composition of claim 1 , further comprising a pharma- ceutically acceptable carrier, excipient or diluent.

6. The pharmaceutical composition according to claim 1 , which is formulated into an oral preparation, an injectable preparation or an external preparation.

7. The pharmaceutical composition according to claim 5, wherein the topical agent is any one or more selected from the group consisting of creams, gels, ointments, emulsions, suspensions, sprays, and transdermal patches.

8. A cosmetic composition for preventing or ameliorating allergic diseases, comprising as an active ingredient a pentapeptide consisting of the amino acid sequence of SEQ ID NO:

1.

9. The cosmetic composition according to claim 8, wherein the allergic disease includes one or more selected from the group consisting of allergic dermatitis, contact dermatitis, urticaria, pruritus, psoriasis, and eczema.

10. The cosmetic composition according to claim 9, wherein the allergic dermatitis is atopic dermatitis.

11. The cosmetic composition according to claim 8, further comprising a cosmetically acceptable carrier, excipient or diluent.

12. 9. The cosmetic composition according to claim 8, which is prepared into any one or more dosage forms selected from the group consisting of lotion, lotion, cream, essence, milky lotion, gel, hand cream, lipstick, cleansing foam, cleansing cream, cleansing water, spray, shampoo, rinse, treatment, body cleanser, soap, pack, massage agent, face powder, compact, foundation, two-way cake, and makeup base.

13. A composition for preventing or improving itching, comprising a pentapeptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

Citation Information

Patent Citations

  • Immunosuppressive agents and their use in therapy

    WO2015067712A1